| (2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride | IC50 | 34.3 [1] |
| (2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride | Ki | 33.0 [1] |
| Marimastat | IC50 | 2.9 [1] |
| Marimastat | Ki | 0.7 [1], 1.0 [2], 1.1 [3] |
| Ilomastat | IC50 | 3.0 [1] |
| Ilomastat | Ki | 2.0 [1] |
| Prinomastat | IC50 | 8.2 [1] |
| Prinomastat | Ki | 8.2 [1] |
| Batimastat | IC50 | 1.2 [1] |
| Batimastat | Ki | 0.5 [1] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | IC50 | 34.0 [1] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | Ki | 590.0 [1] |
| n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide | IC50 | 1.9 [1], 3.0 [2], 20.0 [3] |
| n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide | Ki | 1.0 [1], 6.0 [2], 10.0 [3] |
| Methylamino-phenylalanyl-leucyl-hydroxamic acid | IC50 | 3.0 [1], 25.0 [2], 60.0 [3] |
| Methylamino-phenylalanyl-leucyl-hydroxamic acid | Ki | 6.0 [1], 7.0 [2] |
| (R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide | IC50 | 3.0 [1], 5.0 [2], 5.01 [3], 10.0 [4] |
| (R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide | Ki | 2.0 [1] |
| N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)acetamide | IC50 | 2900.0 [1], 12000.0 [2], 50000.0 [3] |
| Cipemastat | IC50 | 2.3 [1] |
| Cipemastat | Ki | 0.3 [1], 3.0 [2], 7000.0 [3] |
| N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide | IC50 | 3000.0 [1] |
| N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide | Ki | 33.0 [1], 77.0 [2], 200.0 [3] |
| n-Hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamide | IC50 | 143.0 [1] |
| 2-(Biphenyl-4-ylsulfonamido)-N-hydroxyacetamide | IC50 | 610.0 [1], 970.0 [2] |
| 2-(Biphenyl-4-ylsulfonamido)-N-hydroxyacetamide | Ki | 365.0 [1] |
| N-Hydroxy-2-[(4-nitro-benzyl)-pentafluorobenzenesulfonyl-amino]-acetamide | IC50 | 3.02 [1] |
| N-Hydroxy-2-[(4-nitro-benzyl)-pentafluorobenzenesulfonyl-amino]-acetamide | Ki | 3.0 [1], 5.0 [2] |
| N-(3-Methoxybenzyl)-4-Oxo-3,4-Dihydroquinazoline-2-Carboxamide | IC50 | 10000.0 [1] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-8-phenoxyoctanehydroximic acid | IC50 | 26.0 [1] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-8-phenoxyoctanehydroximic acid | Ki | 26.0 [1] |
| (2R)-2-[[(2S)-1-[[(2S)-1-Anilino-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid | Ki | 760.0 [1], 770.0 [2] |
| 2-((4-Phenoxyphenylsulfonyl)methyl)thiirane | Ki | 206000.0 [1] |
| (2S,3R)-N-Hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide | IC50 | 2.2 [1], 10.0 [2] |
| Apratastat | IC50 | 33.0 [1], 145.0 [2] |
| CID 6914621 | IC50 | 30000.0 [1] |
| CID 6914621 | Ki | 30000.0 [1] |
| CID 10370504 | IC50 | 51000.0 [1] |
| Mmp inhibitor II | IC50 | 24.0 [1] |
| Mmp inhibitor II | Ki | 24.0 [1] |
| 4-[(4-But-2-ynoxyphenyl)sulfonylmethyl]-N-hydroxy-1-propan-2-ylsulfonylpiperidine-4-carboxamide | IC50 | 8780.0 [1] |
| N-Hydroxy-4-(4-phenylsulfanylphenyl)sulfonyl-1-prop-2-ynylpiperidine-4-carboxamide | IC50 | 5000.0 [1], 8660.0 [2] |
| (6S,7R,10S)-6-N-Hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide | IC50 | 3.0 [1] |
| (6S,7R,10S)-6-N-Hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide | Ki | 1.2 [1] |
| (2S,3R)-2-(Cyclopropylmethylamino)-N-hydroxy-N'-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(3-hydroxyphenyl)methyl]butanediamide | IC50 | 10000.0 [1] |
| (2S,3R)-2-(Cyclopropylmethylamino)-N-hydroxy-N'-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(3-hydroxyphenyl)methyl]butanediamide | Ki | 33160.0 [1] |
| (2S)-2-[[4-(4-Methoxyphenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | IC50 | 1500.0 [1], 8710.0 [2] |
| (2R,3R)-1-[4-[(2-Chloro-4-fluorophenyl)methoxy]phenyl]sulfonyl-N,3-dihydroxy-3-methylpiperidine-2-carboxamide | IC50 | 200.0 [1], 310.0 [2] |
| Benzyl 6-Benzyl-5,7-Dioxo-6,7-Dihydro-5h-[1,3]thiazolo[3,2-C]pyrimidine-2-Carboxylate | IC50 | 30000.0 [1], 100000.0 [2] |
| (8S,11R,12S)-12-N-Hydroxy-8-N-(2-morpholin-4-yl-2-oxoethyl)-2,10-dioxo-11-[[4-[2-(trifluoromethyl)phenyl]phenyl]methyl]-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide | Ki | 2000.0 [1] |
| N-Hydroxy-2-[(4-methoxy-benzenesulfonyl)-(4-nitro-benzyl)-amino]-acetamide | IC50 | 28.18 [1] |
| N-Hydroxy-2-[(4-methoxy-benzenesulfonyl)-(4-nitro-benzyl)-amino]-acetamide | Ki | 28.0 [1] |
| N-Hydroxy-2-[(4-nitro-benzyl)-(nonafluorobutane-1-sulfonyl)-amino]-acetamide | IC50 | 61.66 [1] |
| N-Hydroxy-2-[(4-nitro-benzyl)-(nonafluorobutane-1-sulfonyl)-amino]-acetamide | Ki | 62.0 [1] |
| (3R)-2-[Ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide | Ki | 4.59 [1] |
| Tert-butyl (6S,9R,10S)-10-(hydroxycarbamoyl)-6-(methylcarbamoyl)-9-(2-methylpropyl)-8-oxo-1,7-diazacyclotridecane-1-carboxylate | Ki | 1.0 [1] |
| (6S,7S)-N-Hydroxy-6-[(4-phenylpiperazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 5000.0 [1] |
| 2-[Methyl(4-methoxyphenylsulfonyl)amino]-3-methyl-5-bromobenzohydroximic acid | IC50 | 114.0 [1] |
| N-Hydroxy-2-[2-methylpropyl-(4-phenylphenyl)sulfonylamino]acetamide | IC50 | 4100.0 [1], 4800.0 [2] |
| 2-[Methyl[4-(2-propynyloxy)phenylsulfonyl]amino]-3-methyl-5-bromobenzohydroximic acid | IC50 | 52.0 [1], 113.0 [2] |
| 3-{2-Cyclohexyl-1-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-ethylcarbamoyl}-6-p-tolyl-hexanoic acid | Ki | 47800.0 [1], 47863.01 [2] |
| 3-[1-(2-Carboxy-ethylcarbamoyl)-2-cyclohexyl-ethylcarbamoyl]-6-p-tolyl-hexanoic acid | Ki | 100000.0 [1] |
| 3-[2-Cyclohexyl-1-(2-methoxycarbonyl-ethylcarbamoyl)-ethylcarbamoyl]-6-p-tolyl-hexanoic acid | Ki | 41400.0 [1], 41686.94 [2] |
| (RS)-3-(2-Cyclohexyl-1-phenethylcarbamoyl-ethylcarbamoyl)-6-phenyl-hexanoic acid | Ki | 20892.96 [1], 21100.0 [2] |
| 3-[2-Cyclohexyl-1-(4-morpholin-4-yl-butylcarbamoyl)-ethylcarbamoyl]-6-p-tolyl-hexanoic acid | Ki | 55000.0 [1], 100000.0 [2] |
| (3R)-3-[[(2S)-3-Cyclohexyl-1-oxo-1-[2-(4-sulfamoylphenyl)ethylamino]propan-2-yl]carbamoyl]-6-(4-methoxyphenyl)hexanoic acid | Ki | 10000.0 [1], 100000.0 [2] |
| (3R)-6-(4-Chlorophenyl)-3-[[(2S)-3-cyclohexyl-1-oxo-1-[2-(4-sulfamoylphenyl)ethylamino]propan-2-yl]carbamoyl]hexanoic acid | Ki | 54954.09 [1], 55000.0 [2] |
| 3-(1-Carbamoyl-2-cyclohexyl-ethylcarbamoyl)-6-phenyl-hexanoic acid | Ki | 100000.0 [1] |
| 3-[2-Cyclohexyl-1-(2-methoxycarbonyl-ethylcarbamoyl)-ethylcarbamoyl]-6-phenyl-hexanoic acid | Ki | 57543.99 [1], 57800.0 [2] |
| 3-[1-(3-Carbamoyl-propylcarbamoyl)-2-cyclohexyl-ethylcarbamoyl]-6-phenyl-hexanoic acid | Ki | 28183.83 [1], 28400.0 [2] |
| 3-{2-Cyclohexyl-1-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-ethylcarbamoyl}-6-phenyl-hexanoic acid | Ki | 39810.72 [1], 40200.0 [2] |
| (S)-3-((S)-2-Cyclohexyl-1-phenethylcarbamoyl-ethylcarbamoyl)-6-phenyl-hexanoic acid | Ki | 19952.62 [1], 20000.0 [2] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-7-(benzyloxy)heptanehydroximic acid | Ki | 1450.0 [1], 1500.0 [2] |
| (R)-3-[[[(S)-2-Phenyl-1-(N-methylcarbamoyl)ethyl]amino]carbonyl]-7-phenoxyheptanehydroximic acid | Ki | 8.0 [1] |
| 3-(2-Cyclohexyl-1-phenethylcarbamoyl-ethylcarbamoyl)-6-p-tolyl-hexanoic acid | Ki | 21877.62 [1], 22100.0 [2] |
| (2R)-N-[(2S)-3-Cyclohexyl-1-oxo-1-(2-phenylethylamino)propan-2-yl]-N'-hydroxy-2-(3-phenylpropyl)butanediamide | Ki | 203.0 [1] |
| (2R)-4-(1,3-Dioxobenzo[f]isoindol-2-yl)-2-[[(2S)-4-methyl-1-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]amino]butanoic acid | IC50 | 20.0 [1], 34.0 [2] |
| (2R)-4-(1,3-Dioxobenzo[f]isoindol-2-yl)-2-[[(2S)-4-methyl-1-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]amino]butanoic acid | Ki | 5.0 [1] |
| Tanomastat | IC50 | 5000.0 [1] |
| Tanomastat | Ki | 5000.0 [1] |
| N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid | IC50 | 300.0 [1] |
| N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid | Ki | 174.0 [1] |
| (3S)-4-{[4-(But-2-ynyloxy)phenyl]sulfonyl}-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide | IC50 | 6.6 [1], 7.0 [2] |
| Unii-Q56UE7E40Y | IC50 | 5000.0 [1] |
| (R)-5-(6-Cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide | IC50 | 10000.0 [1] |
| N-[(1S)-1-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamide | IC50 | 8900.0 [1], 50000.0 [2] |
| 2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-methylbutanamide | IC50 | 42.66 [1] |
| 2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-methylbutanamide | Ki | 43.0 [1] |
| (R)-N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamide | IC50 | 147.0 [1], 490.0 [2] |
| Methyl rosmarinate | IC50 | 14700.0 [1], 14740.0 [2] |
| cis-2-Aminocyclohexylcarbamoylphosphonic acid | IC50 | 100000.0 [1] |
| N-[(2S)-1-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]-N-hydroxyformamide | IC50 | 4600.0 [1] |
| 2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxyacetamide | IC50 | 60.26 [1] |
| 2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxyacetamide | Ki | 60.0 [1] |
| N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | IC50 | 10000.0 [1] |
| N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | Ki | 10000.0 [1] |
| 3-[(4'-Cyanobiphenyl-4-Yl)oxy]-N-Hydroxypropanamide | IC50 | 10.0 [1], 3300.0 [2] |
| 4-{[1-Methyl-2,4-Dioxo-6-(3-Phenylprop-1-Yn-1-Yl)-1,4-Dihydroquinazolin-3(2h)-Yl]methyl}benzoic Acid | IC50 | 30000.0 [1] |
| (2R)-N'-Hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2-[(3-hydroxyphenyl)methyl]butanediamide | Ki | 30953.0 [1] |
| (3R,4R)-N-Hydroxy-4-[[4-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]benzoyl]amino]oxane-3-carboxamide | Ki | 4948.0 [1], 10000.0 [2] |